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wFinal Results of the Protected Superficial Femoral Artery Trial Using
the Filter Wire EZ System
Muller-Hulsbeck S, Humme TH, Schafer JP, et al. Cardiovasc Intervent
Radiol 2010;33:1120-7.
Conclusion: A distal protection device during femoral popliteal inter-
ventions reduces distal migration of debris.
Summary: The study evaluated the safety and efficacy of a single distal
protection device (Filter Wire EZ Embolic Protection System, Boston
Scientific, Mountain View, Calif) for capturing debris during superficial
femoral artery (SFA) percutaneous interventions. An additional aim was to
define the incidence of distal embolization during SFA interventions. This
was a prospective, single-center registry. The study included 30 patients
suitable for percutaneous transluminal angioplasty (PTA). Primary end
points were occurrence of distal embolization, decreased runoff, improve-
ment in ankle-brachial index (ABI), and number of filters containing emboli.
Secondary end points included procedural or device-related death and/or
clinical target lesion revascularization, device delivery, deployment success,
and incidence of embolic recovery. Procedural success was defined as30%
residual stenosis, with no worsening of distal runoff as determined by
angiography. The study enrolled 29 patients with 30 treated limbs, suitable
for PTA, between February 2007 and March 2008. Claudication was the
indication for intervention in 26 patients and critical limb ischemia in 3. One
patient underwent treatment in both legs. The average degree of stenosis
was 86% 7%, and stenosis length ranged from 8 to 88 mm. No procedural
or device-related complications occurred. Average degree of residual steno-
sis was 10 %  10%. ABI improved from 0.56  0.16 to 0.92  0.19 (P 
.05). At 1 month, there was no ultrasound-detected waist stenoses or
dissections. Microscopic debris was found in 27 of the 30 filters used.
Particle size was 1200 640 m (range, 90-2000 m). Histologic analysis
indicated debris consisted of platelets, erythrocytes, inflammatory cells,
extracellular matrix, and cholesterol. There was no correlation between
lesion morphology and type of debris.
Comment:This is a small, single-center, nonrandomized commercially
sponsored study with the first author having a consulting arrangement with
the study sponsor. The study is obviously good marketing material for the
manufacture of the FilterWire EZ System. However, assuming the author’s
observations are accurate, the study should bring some measure of concern
to all who perform catheter-based SFA interventions, because these inter-
ventions seem to be nearly uniformly associated with distal embolization.
Long-term clinical implications of these distal emboli remain to be defined,
but as someone once said, they may not be bad, but they can’t be good! The
true clinical utility of embolic protection devices in all vascular beds remains
an intriguing, and certainly a potentially profitable, avenue of research.
Pathogenesis of Acute Aortic Dissections: A Finite Element Stress
Analysis
Nathan DP, Zu C, Gorman JH 3rd, et al. Ann Thorac Surg 2011;91:
458-64.
Conclusion: Wall stress in the thoracic aorta peaks above the sinotu-
bular junction and distal to the left subclavian artery origin. Wall stress may
contribute to the pathophysiology of thoracic aortic dissection.
Summary: In most cases, type A and type B thoracic aortic dissections
originate with entry tears, respectively, above the sinotubular junction or
distal to the left subclavian artery origin. Although thoracic dissection is
influenced by many components, including aortic diameter, hypertension,
and decreases in wall strength associated with Marfan syndrome or Ehlers-
Danlos syndrome, the precise mechanistic rationale for origin of thoracic
type A and type B dissections is not understood. The authors hypothesized
that a biomechanical approach to predicting thoracic aortic walls stress may
better define the risk of thoracic aortic dissection in individual patients. They
mapped patterns of wall stress in the thoracic aorta in normal individuals,
extrapolating wall stress patterns from normal individuals to those with
potential dissection. They identified 47 patients whose thoracic aorta was
normal by electrocardiogram-gated computed tomography angiography.
The thoracic aorta was segmentally reconstructed and triangulated to create
a geometric mesh with the ABAQUS/Explicit 6.3 program (HKS Inc,
Pawtucket, RI). A systolic pressure load of 120 mm Hg was then used to
construct a finite element analysis and to predict regional thoracic aortic wall
stress. Local maximum wall stress was highest in the sinotubular junction in
the ascending aorta and distal to the origins of the supra-aortic vessels,
including the left subclavian artery, in the aortic arch. No errors of maximum
wall stress were identified in the descending thoracic aorta. A comparison of
areas of mean peak wall stress above the sinotubular junction (0.43  0.77
p
iPa), distal to the left subclavian artery origin (0.021  0.77 MPa), and in
he descending thoracic aorta (0.06  0.01 MPa) demonstrated significant
evels of wall stress by aortic region (P  .001).
Comment: The data indicate that there are peaks in wall stress in the
ormal thoracic aorta above the sinotubular junction and just distal to the
rigin of the left subclavian artery. The implication that peaks in wall stress
ay contribute to aortic dissection is a bit of “guilt by association.” Prevent-
ng thoracic aortic dissection is likely to be a multifaceted task. Diameter,
ccording to Laplace’s Law, is currently used as a noninvasive surrogate of
ortic wall stress. Surgical intervention is timed to occur before wall stress
xceeds the maximal tensile strength of the aorta, estimated at about 800
Ps. Although the risk of acute aortic events is currently correlated roughly
ith size, even small aortas can have fatal dissections and ruptures. Improv-
ng wall strength of the aorta, decreasing expansion rates, and calculations of
all sheer stress will all likely, in the future, be used in the management of
atients with thoracic and abdominal aortic disease.
esults of Single- and Two-Vessel Mesenteric Artery Stents for
hronic Mesenteric Ischemia
algor RD, Oderich GS, McKusick MA, et al. Ann Vasc Surg 2010;24:
094-101.
Conclusions: Stenting of both the celiac artery and the superior
esenteric artery (SMA) for chronic mesenteric ischemia (CMI) does not
educe recurrent symptoms or reinterventions compared with stenting of the
MA alone. Isolated celiac stenting carries a high risk of symptom recur-
ence.
Summary: Mesenteric artery stenting is gaining wider acceptance for
he treatment of CMI. It relieves symptoms of CMI in 78% to 100% and has
ower morbidity and mortality compared with open reconstruction. How-
ver, the durability of mesenteric stenting is questioned. Primary patencies
ave ranged from 30% to 82%, and 17% to 64% of patients have recurrent
ymptoms at 2 years of follow-up (Atkins MD et al [J Vasc Surg 2007;45:
162-71]; AbuRahma AF et al [J Endovasc Ther 2003;10:1046-53]). It is
enerally agreed that the SMA is the primary target vessel for revasculariza-
ion for patients with CMI. In open surgical procedures, it is debated
hether revascularization of the SMA alone is adequate treatment. In
ndovascular therapy for CMI, it is also unclear whether stenting of the
eliac artery in addition to the SMA adds to the durability treatment. The
urpose of this study was to describe the outcomes of single-vessel vs
wo-vessel mesenteric stent placement in patients with CMI secondary to
therosclerotic disease. The authors reviewed 101 patients (41 men, mean
ge 73  13 years) who were treated with mesenteric artery stents from
998 to 2008. Patients treated with single-vessel SMA stents (group A),
wo-vessel celiac artery and SMA stents (group B), and patients treated with
solated celiac artery stenting (group C), were reviewed with respect to
linical data and outcomes. The groups were analyzed for differences in
orbidity and mortality and freedom from recurrent symptoms and reinter-
ention. There were 61 patients in group A, 24 in group B, and 16 in group
. Demographics, cardiovascular risk factors, and clinical presentation were
imilar among the three groups. The three groups had similar early mortality
2%, 4%, and 0%, respectively), morbidity (18%, 26%, and 12%, respectively),
nd symptom relief (95%, 78%, and 100%, respectively). Freedom from
eintervention at 1 and 3 years was similar in group A (86% 5% and 50%
%), group B (67%  11% and 67%  11%), and group C (63%  13% and
3% 113%). Differences in freedom from restenosis were similar at 1 and 3
ears in group A (54%  7% and 44%  9%), group B (47%  12% and
9%  12%), and group C (43%  13% and 34  13%). Primary and
econdary patencies at 3 years were 57% and 96% for SMA stents and 61%
nd 87%, respectively, for celiac stents (P .05). Celiac artery stenting alone
as associated with symptom recurrence in 38% compared with recurrence
ates of 18% in patients who underwent SMA stent placement (P  .06).
wo-vessel stenting was associated with more complications (33%) com-
ared with stenting of the SMA (18%) or celiac artery (6%) alone. The higher
omplication rate was due to more interprocedural complications (residual
tenosis or dissection).
Comment: There was no added benefit to two-vessel stenting com-
ared with single-vessel stenting for treatment of CMI. Long-term results
ere similar, with nearly identical rates of restenosis, reintervention, and
ymptom recurrence. Two-vessel stenting was associated with more compli-
ations. The study was limited by its retrospective design. It is possible there
as a bias toward placement of two stents in patients withmore symptoms or
hen the anatomy of the SMA was suboptimal for stenting. It is conceivable
atients with poor collateralization between the celiac and SMA with signif-
cant gastric ischemic manifestations of CMImay benefit from stenting both
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